|
|
|
|
Nrx Pharmaceuticals Inc (NASDAQ: NRXP) |
|
Price: $2.0800
$0.01 
0.483%
|
| Day's High:
| $2.12
| Week Perf:
| 1.46 %
|
| Day's Low: |
$ 2.03 |
30 Day Perf: |
-15.1 % |
| Volume (M): |
196 |
52 Wk High: |
$ 6.01 |
| Volume (M$): |
$ 407 |
52 Wk Avg: |
$2.48 |
| Open: |
$2.09 |
52 Wk Low: |
$1.10 |
|
|
| Market Capitalization (Millions $) |
22 |
| Shares
Outstanding (Millions) |
11 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-25 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Nrx Pharmaceuticals Inc
Nrx Pharmaceuticals Inc is a pharmaceutical company that focuses on developing innovative therapies for various medical conditions. They specialize in the research and development of neurology and psychiatry drugs. The company aims to improve the lives of patients suffering from neurological disorders such as epilepsy, Parkinson's disease, and psychiatric conditions like schizophrenia and depression. Nrx Pharmaceuticals Inc strives to discover novel treatments and bring them to the market to provide better healthcare options to individuals in need.
Company Address: 1201 Orange Street, Suite 600 Wilmington 19801 DE
Company Phone Number: 254-6134 Stock Exchange / Ticker: NASDAQ NRXP
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Nrx Pharmaceuticals Inc
The stock market is a dynamic and ever-changing landscape, with different sectors constantly being monitored and analyzed. One such sector that is currently under scrutiny is the Major Pharmaceutical Preparations industry. Experts are closely examining the first quarter results of 2024, particularly focusing on a company that has not yet declared any revenue.
Despite the absence of revenue, the company has made impressive progress in managing its day-to-day operations. In fact, their decisions in this regard have surpassed those made during the same period in the previous year. This is particularly noteworthy in the development cycle, an essential aspect of the pharmaceutical industry.
|
| Nrx Pharmaceuticals Inc
NRx Pharmaceuticals Inc. (NRXP) has recently released its fourth quarter and full-year 2023 financial results, which have left shareholders somewhat surprised. While the company's revenue experienced some moderations during the October to December 31 period in 2023, investors paid close attention to the operating shortfall, which came in at $-4.406 million during the same timeframe.
However, it is important to note that NRXP has made significant progress in improving its financial performance. Compared to the fiscal period ending December 31, 2022, the company's operating shortfall has significantly decreased from $-9.889 million to the current $-4.332 million. This clearly indicates that NRXP is on a path to becoming more economically efficient.
|
| Nrx Pharmaceuticals Inc
NRX Pharmaceuticals Inc, a major player in the pharmaceutical industry, has experienced significant improvements in its stock performance over the past month. During this period, the company's stock has seen an impressive increase of 14.44%. Additionally, over the past five trading days, NRX Pharmaceuticals Inc's stock has improved by 3.21%. Despite these positive developments, it is worth noting that NRX Pharmaceuticals Inc's stock is currently trading on the NASDAQ at a considerable 51.7% below its 52-week average.
To better understand the recent stock performance of NRX Pharmaceuticals Inc, it is important to analyze the company's financials for the third quarter of 2023. During this period, the company reported an operating loss of $-5.808 million. It is worth mentioning that NRX Pharmaceuticals Inc did not mention any revenue for this reporting period, making it crucial to consider other indicators to assess the company's situation.
When comparing the results of the third quarter of 2023 to the same period in 2022, NRX Pharmaceuticals Inc has showcased positive signs of improvement. In the third quarter of 2022, the company reported an operating loss of $-9.141 million, highlighting a significant reduction in losses. This reduction in operating losses demonstrates the company's efforts to streamline its operations and become more cost-effective.
|
| Nrx Pharmaceuticals Inc
As an avid follower of the financial markets and a regular reader of the Wall Street Journal, I'd like to provide my interpretation of the recent financial results of Nrx Pharmaceuticals Inc. While large companies in the Major Pharmaceutical Preparations sector are often in the spotlight, it's important not to overlook the performance of lesser-known companies such as Nrx Pharmaceuticals Inc.
According to the recent report, Nrx Pharmaceuticals Inc has reported an operating shortfall of $-8.188 million for the second quarter of 2023. Compared to the same period in 2022, the present decisions made by the company have resulted in a significant decline in productivity. This is a noteworthy observation, especially considering Nrx Pharmaceuticals Inc primarily operates in the development stage.
|
| Nrx Pharmaceuticals Inc
Nrx Pharmaceuticals Inc is a smaller player in the Major Pharmaceutical Preparations sector, compared to the bellwethers in the field. However, the company has reported encouraging news in its recent financial report for the first quarter of 2023. The operating deficit for the company has significantly reduced from the first quarter of 2022, from $-15.705 million to $-9.435 million in the most recent financial report. This improvement in operating deficit has provided investors with confidence in the company and its future prospects.
Nrx Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of novel therapies for the treatment of central nervous system disorders and chronic pain. The company's pipeline consists of products that have the potential to address significant unmet medical needs in these areas. The company's flagship product, NRX-101, is currently in clinical development for the treatment of major depressive disorder and suicidal ideation.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.24 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
0.14 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.24 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
0.14 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
0.67% 